Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution for the Treatment of Motoric Cognitive Risk Syndrome

Inclusion Criteria:

• Sign the informed consent form
• Capability of independent living (capability of dressing, bathing, walking, andbed-chair transfer)
• Met Motoric Cognitive Risk Syndrome (MCR) criteria: Single task slow gait ( male 60 to 74 y, gait <75.4 cm/s; male ≥ 75 y, gait < 59.1 cm/s;female 60 to 74 y, gait <70.0 cm/s; female ≥ 75 y, gait < 48.3 cm/s) And The MontrealCognitive Assessment (MoCA) ≤ 26 (≥ 12 education year) or MoCA ≤ 25 (< 12 education year)
• Anticipated good compliance per protocol

Exclusion Criteria:

• Illiteracy
• The Mini-Mental State Examination (MMSE) ≤ 23
• Medical history of mental illness such as schizophrenia, severe anxiety anddepression.
• Medical history of Alzheimer's disease, Parkinson's disease, frontotemporal dementiaor Huntington's disease.
• Dementia caused by other causes (such as central nervous system trauma, tumor,infection, metabolic disease, normal pressure hydrocephalus, folic acid, vitamin B12deficiency, thyroid Inferior functions, etc.).
• History of epilepsy, or taking anti-epileptic drugs.
• History of myocardial infarction or stroke
• History of malignant tumor
• Coagulation disorder, systemic bleeding; or previous coagulation disorder or systemicbleeding disease history.
• History of thrombocytopenia or neutropenia.
• History of blood system diseases or liver function abnormalities caused by medication
• Contraindications to ginkgo drugs and a history of known allergies.
• Aphasia, severe hearing or visual impairment, dominant hemiplegia, and other impactson cognitive evaluation The status of the test.
• Known slow gait causes (non-neurological causes [such as: arthritis, heart disease]and neurological causes [bias Paralysis, ataxia, spasticity, Parkinson's disease andfrontal lobe disease])
• Severe heart and lung diseases (coronary heart disease, LVEF<40%, NYHA heart failuregrade ≥III, asthma asthma).
• Severe arrhythmia, heart rate >120bpm or <50bpm. (17) Blood pressure <90/60mmHg
• Severe anemia, Hb<100g/L
• Severe liver or renal insufficiency (ALT > 2 times the upper limit of normal or AST > 2 times the upper limit of normal; Creatinine >1.5 times the upper limit of normal)
• Leukopenia (<2×109/l) or thrombocytopenia (<100×109/l)
• Currently enrolled in other drug or medical device study
• Planned any surgery within 6 months at screening
• Considered by investigators as unsuitable participant of this study